相关实验视频

Updated: Jul 23, 2025

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

质瘤血管新生是由ELK3激活HIF-1 / VEGF-A信号轴的激活所促进的

Mou Yueyang^1,2, Hu Yaqin¹, Xue Guolian¹

¹College of Life Sciences, Northwest University, Xi'an, China.

|July 14, 2023

概括

通过激活HIF-1/VEGF-A通路,ELK3蛋白促进结质瘤血管生成. 准ELK3可能会改善抗血管性疗法,从而改善患者在质瘤治疗中的结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

抗血管生成疗法可以改善质瘤的无进展生存率,但不能改善整体生存率.
在质瘤血管生成中ELK3的作用需要进一步研究以改善治疗策略.

研究的目的:

为了研究ELK3在质瘤血管生成中的作用.
探索ELK3作为质瘤的潜在治疗点.

主要方法:

400名质瘤患者的组织微阵列和免疫组织化学.
在体外测试 (CCK-8,EDU,transwell,流动细胞计,管形成,大鼠大动脉环,matrigel插头) 来评估ELK3的功能.
在裸体小鼠中进行ELISA,Western blot,CGGA数据集分析和正体移植,以评估ELK3对血管生成和瘤进展的影响.

主要成果:

质瘤中ELK3的升高调节,与预后不佳有关.
ELK3促进质瘤细胞增殖,转移和细胞周期进展,同时抑制细胞亡.
通过促进HIF-1降解,减少瘤进展和血管新生,ELK3 Knockdown抑制了VEGF-A的分泌 in vitro 和 in vivo.

结论:

通过HIF-1/VEGF-A信号轴,ELK3对质瘤血管生成至关重要.
ELK3 作为结质瘤的预后标志物.
准ELK3为增强抗血管原性疗法在质瘤治疗中的潜力.

关键词:

血管新生的产生.在ELK3中,ELK3是ELK3.质瘤是一种质瘤.在HIF-1的基础上.在VEGF-A的基础上.

更多相关视频

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

相关概念视频

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...